3α,7β-Dihydroxy-5β-cholan-24-oate 3α,7β-二羟基-5β-胆碱-24-油酸
CAS 128-13-2 MFCD00003680
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
分类
- {Chemicalbo
- {SNA} Anionic Detergents, Bile Salts, Bile acids and Derivatives, Cell Culture, Chemical ER Chaperones, Detergents N to Z, Detergents by Applications, Endoplasmic Reticulum Stress, Gene Regulation, Phototherapy, Sterol Lipids, 代谢组学, 代谢通路, 化学预防剂, 去垢剂, 抗肿瘤药物, 生化试剂, 癌症研究, 细胞信号转导和神经科学, 细胞生物学, 胆汁酸代谢, 脂类
- {SNA} Anionic Detergents, Antitumor Agents, Bile Acid Metabolism, Bile Salts, Bile acids and Derivatives,
- {SNA} Analytical Standards,
- {SNA} Anionic D
产品应用
- 阴离子去垢剂,用于生化研究。
相关文献及参考
- [2]. Kumar D, et al. Use of ursodeoxycholic acid in liver diseases. J Gastroenterol Hepatol. 2001 Jan;16(1):3-14.
- [3]. Biao Nie, et al. Specific Bile Acids Inhibit Hepatic Fatty Acid Uptake in Mice. Hepatology. 2012 Oct;56(4):1300-10.
- Merck: 14,9889
- Merck: 14,9889 Beilstein:10(3)1635
- [1]. Jackson H, et al. Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. Hepatology. 2007 Oct;46(4):1131-7.
- [1]. Jackson H, et al. Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. Hepatology. 2007 Oct;46(4):1131-7.
- [2]. Kumar D, et al. Use of ursodeoxycholic acid in liver diseases. J Gastroenterol Hepatol. 2001 Jan;16(1):3-14.
- [3]. Biao Nie, et al. Specific Bile Acids Inhibit Hepatic Fatty Acid Uptake in Mice. Hepatology. 2012 Oct;56(4):1300-10.
安全信息
- P262 Do not get in eyes, on skin, or on clothing. 不要接触眼睛,皮肤或衣服。
- H303 May be harmfully swallowed 吞食可能有害
GHS Symbol
- R36/37/38 Irritating to eyes, respiratory system and skin 对眼睛、呼吸系统和皮肤有刺激性
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 1 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : 85IQAH "Modern Pharmaceuticals of Japan, IV," Tokyo, Japan Pharmaceutical, Medical and Dental Supply Exporters' Assoc., 1972 Volume(issue)/page/year: -,109,1972
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 310 mg/kg TOXIC EFFECTS : Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold REFERENCE : KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 9,3159,1975
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 700 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : BCFAAI Bollettino Chimico Farmaceutico. (Societa Editoriale Farmaceutica, Via Ausonio 12, 20123 Milan, Italy) V.33- 1894- Volume(issue)/page/year: 126,282,1987
TYPE OF TEST : LD50 - Lethal dose, 5
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 4600 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : BCFAAI Bollettino Chimico Farmaceutico. (Societa Editoriale Farmaceutica, Via Ausonio 12, 20123 Milan, Italy) V.33- 1894- Volume(issue)/page/year: 126,282,1987
{haza
TYPE OF TEST : Mutation in microorganisms TEST SYSTEM : Yeast - Saccharomyces cerevisiae DOSE/DURATION : 51 mmol/L REFERENCE : ARTODN Archives of Toxicology. (Springer-Verlag, Heidelberger Pl. 3, D-1000 Berlin 33, Fed. Rep. Ger.) V.32- 1974- Volume(issue)/page/year: 60,192,1987
TYPE OF TEST : Mutation in microorganisms TEST SYSTEM : Bacteria - Salmonella typhimurium DOSE/DURATION : 40 mg/L REFERENCE : MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 158,45,1985
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE : 1200 mg/kg SEX/DURATION : female 9-14 day(s) after conception TOXIC EFFECTS : Reproductive - Maternal Effects - other effects Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) REFERENCE : KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 9
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rabbit DOSE : 65 mg/kg SEX/DURATION : female 6-18
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE : 1200 mg/kg SEX/DURATION : female 7-12 day(s) after conception TOXIC EFFECTS : Reproductive - Maternal Effects - other effects REFERENCE : KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 9,3223,1975
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE : 1200 mg/kg SEX/DURATION : female 9-14 day(s) after conception TOXIC EFFECTS : Reproductive - Maternal Effects - other effects Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) REFERENCE : KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 9,3223,
其他信息
- MSDS 信息:3alpha,7beta-Dihydroxy-6beta-cholan-24-oic acid(128-13-2).msds
- 上游原料:甲醇 --> 二乙二醇 --> 2,3-丁二酮 --> 铬酸钾 --> 鹅去氧胆酸 --> 5-Β-胆烷酸 --> 胆酸甲酯 --> 乙酰胆酸
- 味苦。易溶于乙醇、冰乙酸,微溶于氯仿、乙醚,几乎不溶于水。半数致死量1000mg/kg(大鼠,腹腔)、310mg/kg(大鼠,静脉)。
- 用途二:胆石溶解药。主要用于不宜手术治疗的胆固醇型胆结石,尤其是胆囊功能基本正常、结石直径在15mm以下、透X线、非钙化型的浮动胆固醇结石的治愈率高。对中毒性肝炎、胆囊炎、原发性硬化性胆管炎、原发性胆汁淤积性肝硬化也有一定的治疗效果。提高α-干扰素治疗慢性丙型肝炎的疗效。有腹泻,罕见便秘、过敏反应、瘙痒、头痛、头晕、胃痛、胰腺炎及心动过缓等。胆道完全阻塞和严重
- Acros Organics:熊果去氧胆酸/熊去氧胆酸 Ursodeoxycholic acid, 99%(128-13-2)
- 熊去氧胆酸价格(试剂
- 方法一:方法一、以鹅去氧胆酸为原料 3α, 7α-二乙酰胆酸甲酯的制备 取无水甲醇36ml,通入1g干燥氯化氢气体,加胆酸12g,搅拌,加热回流20-30min,室温放置数小时后析出晶体,冷冻,过滤,用乙醚洗涤,干燥,得胆酸甲酯。取胆酸甲酯2g,加苯9.6ml,加吡啶2.4ml,加乙酐2.4ml,振摇10-15min,室温放置20h,将反应液倒入100ml水中,除去苯层,反复用蒸馏水洗涤,回收溶剂,固体残渣用石油醚洗涤1次,用甲醇-水溶液重结晶,得3α,7α-二乙酰胆酸甲酯。 胆酸→胆酸甲酯→3α,7α-二乙酰胆酸甲酯 鹅去氧胆酸的制备 取二乙酰胆酸甲酯1.5g,加乙酸24 ml,加铬酸钾溶液(取铬酸钾0.76g溶于1.8ml水中),加热至40℃,反应8h,加水120ml,振摇片刻,放置12h,过滤,用蒸馏水洗至中性,干燥,得3α,7α-二乙酰氧基- 12-酮基胆烷酸甲酯,简称12-酮。取12-酮15g,加二乙二醇醚150ml,加80%水合肼溶液15ml,加氢氧化钾15g,加热至30℃回流15h,升温至195-200℃,回流2.5h,升温至217℃反应片刻,冷却至190℃,加水合肼溶液0.7ml,在3h内由215℃升温至220℃,冷却,加蒸馏水600ml,加10%硫酸调pH 3,析出结晶,过滤,水洗至中性,加乙酸乙酯,弃去水层,有机层用水洗1-2次,减压蒸馏,得白色3α,7α-二羟基胆烷酸,即鹅去氧胆酸。 3α,7α-二乙酰胆酸甲酯→3α,7α-二乙酰氧基-12-酮基胆烷酸甲酯→3α,7α-二羟基胆烷酸(鹅去氧胆酸) 熊去氧胆酸精品的制备 取鹅去氧胆酸2g,加100ml乙酸,加乙酸钾20g,振摇溶解,加铬酸钾1.5g(溶于10ml水中),室温放置过夜,加水200ml,析出结晶,过滤,水洗,干燥,得3α-羟基-7-酮基胆烷酸。取3α-羟基-7-酮基胆烷酸4g,加正丁醇100ml,加热至约115℃,分次加入金属钠8g,逐渐有白色浆状物析出,继续反应30min,加水120ml,搅拌升温溶解透明,减压蒸去有机层,残渣加水500ml,溶解,过滤,滤液加10%硫酸调pH3,有白色絮状物沉淀,过滤,水洗至中性,干燥,加乙酸乙酯洗涤,稀乙醇结晶,得3α,7β-二羟基胆烷酸,即熊去氧胆酸精品。 鹅去氧胆酸[铬酸钾]→3α-羟基-7-酮基胆酸[金属钠,115℃]→3α, 7β-二羟基胆烷酸(熊去氧胆酸) 方法二、以猪胆
- 参考质量标准:原料药 中国药典2000年版1006页 指标名称 指标 指标名称 指标 含量(C24H40O4)/% ≥98.5/干燥失重/% ≤1.0 比旋度(40mg/ml无水乙醇)/+59.0°-+62.0°/炽灼残渣/% ≤0.2 重金属 ≤百万分之二十 异臭/无/砷盐/% ≤0.0002 氯化物/% ≤0.02/硫酸盐/% ≤0.05 钡盐 无 片剂 中国药典2000年版1006页 指标名称 指标 指标名称 指标 含量(C24H40O4)/% 95.0-105.0/检查/符合片剂规定
- 熊去氧胆酸,主要成分是3a,7β- 二羟基-5β- 胆甾烷-24-酸,为有机化合物,无臭,味苦。本品在乙醇中易溶,在氯仿中不溶;在冰醋酸中易溶,在氢氧化钠试液中溶解。医学上用于增加胆汁酸分泌,并使胆汁成分改变,降低胆汁中胆固醇及胆固醇脂,有利于胆结石中的胆固醇逐渐溶解。